Reuters: Sanofi diet drug misses mark in heart study

[NaDiNe]

Sanofi diet drug misses mark in heart study
      

CHICAGO (Reuters) - The Sanofi-Aventis SA weight loss drug rimonabant failed to slow heart disease by a key measure in obese patients with fat around the middle, and it significantly increased the risk of anxiety and depression, U.S. researchers said on Tuesday.
<p>You are not allowed to view links. Register or Login</p><div class="feedflare">
You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login You are not allowed to view links. Register or Login
</div><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
      

You are not allowed to view links. Register or Login